1. Home
  2. CTNM vs BRSP Comparison

CTNM vs BRSP Comparison

Compare CTNM & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

SELL

Current Price

$9.57

Market Cap

550.7M

Sector

N/A

ML Signal

SELL

Logo BrightSpire Capital Inc.

BRSP

BrightSpire Capital Inc.

SELL

Current Price

$3.28

Market Cap

528.9M

Sector

Real Estate

ML Signal

SELL

Company Overview

Basic Information
Metric
CTNM
BRSP
Founded
2009
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
550.7M
528.9M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
CTNM
BRSP
Price
$9.57
$3.28
Analyst Decision
Buy
Buy
Analyst Count
8
8
Target Price
★ $21.43
$5.75
AVG Volume (30 Days)
596.9K
★ 1.9M
Earning Date
11-03-2026
10-27-2026
Dividend Yield
N/A
★ 19.94%
EPS Growth
0.46
★ 75.24
EPS
N/A
★ 0.25
Revenue
N/A
★ $330,587,000.00
Revenue This Year
N/A
$4.72
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$12.84
Revenue Growth
N/A
★ N/A
52 Week Low
$6.73
$3.05
52 Week High
$17.79
$6.17

Technical Indicators

Market Signals
Indicator
CTNM
BRSP
Relative Strength Index (RSI) 46.25 37.41
Support Level $8.59 N/A
Resistance Level $13.72 $3.87
Average True Range (ATR) 0.77 0.16
MACD 0.23 -0.01
Stochastic Oscillator 42.33 26.33

Price Performance

Historical Comparison
CTNM
BRSP

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

About BRSP BrightSpire Capital Inc.

BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.

Share on Social Networks: